dose-ranging study to assess the efficacy and safety of ciclesonide HFA nasal aerosol in adult and adolescent patients 12 years and older with Seasonal Allergic Rhinitis (SAR) (BY9010/M1-602)

Study identifier:BY9010/M1-602

ClinicalTrials.gov identifier:NCT00807053

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A double-blind, randomized, placebo-controlled, parallel group, multicenter, dose-ranging study to assess the efficacy and safety of ciclesonide HFA nasal aerosol in adult and adolescent patients 12 years and older with Seasonal Allergic Rhinitis (SAR)

Medical condition

Rhinitis, Allergic, Seasonal

Phase

Phase 2

Healthy volunteers

No

Study drug

Ciclesonide HFA, Placebo

Sex

All

Actual Enrollment

480

Study type

Interventional

Age

12 Years +

Date

Study Start Date: 01 Apr 2007
Primary Completion Date: 01 Jun 2007
Study Completion Date: 01 Jul 2007

Study design

Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment

Verification:

Verified 01 Sept 2016 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria